Resources
15 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 4/4/2024 (updated 4/18/2024)
If you or someone else is in immediate danger, call 911 to seek immediate assistance.
Below are resources you can contact if you are seeking assistance or information. All resources are intended for informational purposes only.
Posted 2/18/2021 (updated 4/4/2024)
Opioid use disorder (OUD), a chronic disease, is a major public health problem. Despite availability of effective treatment, too few people receive it and treatment retention is low. Understanding barriers and facilitators of treatment access and retention is needed to improve outcomes for people with OUD.
In this study we sought to assess 3-month outcomes from a patient-centered practice that included MAT with buprenorphine or naltrexone plus the option to participate in psychosocial treatments. The psychosocial treatments included case management, psychotherapy, peer recovery groups such as Narcotics Anonymous or Smart Recovery, or peer support through a local harm reduction program.
Posted 12/29/2020 (updated 4/4/2024)
Whereas outpatient treatment with medication for opioid use disorder (MOUD) is evidence based, there is a large network of inpatient facilities in the US that are reimbursed by commercial insurers and do not typically offer MOUD. This study is a comparison of rates of overdose and hospitalization after initiation of medication for Opioid Use Disorder in the inpatient vs outpatient setting.
Posted 10/23/2020 (updated 4/3/2024)
The objective of this report was to perform a systematic review of the beneficial and harmful effects of BUP-ER 100 mg and 300 mg for the management of moderate-to-severe OUD in adult patients who have been inducted and clinically stabilized on a transmucosal buprenorphine-containing product.
Posted 10/23/2020 (updated 4/3/2024)
These pilot study results suggest comparable safety and effectiveness of unobserved and office induction and point toward utilization of non-inferiority design during future definitive protocol development.
Posted 10/23/2020 (updated 4/3/2024)
This article offers data regarding offering buprenorphine treatment at a public hospital primary care setting using a home, unobserved induction protocol.
Posted 10/23/2020 (updated 4/3/2024)
The goal of this module is to train providers to initiate patients on buprenorphine safely and effectively.
Posted 7/16/2020 (updated 3/28/2024)
The information in this document was guided by the vision of the U.S. Department of Health and Human Services’ Office on Women’s Health and lessons learned from a 3-year reentry enhancement project conducted across 3 different reentry organizations. The participating pilot sites were the Resonance Center for Women, Inc., the College and Community Fellowship, and the Institute for Health and Recovery . Using the information compiled through this project, this guide was created by the Substance Abuse and Mental Health Services Administration’s GAINS Center for Behavioral Health and Justice Transformation.
Posted 6/16/2020 (updated 3/28/2024)
The most effective therapy for people with opioid use disorder involves the use of Food and Drug Administration-approved medications—methadone, buprenorphine, and naltrexone. Despite evidence that this approach, known as medications for opioid use disorder, reduces relapse and saves lives, the vast majority of jails and prisons do not offer this treatment.
Posted 9/28/2022 (updated 3/27/2024)
Last week, the U.S. Department of Health & Human Services (HHS) introduced the Roadmap for Behavioral Health Integration, to advance the White House Strategy to Address our National Mental Health Crisis announced earlier this year.